Q-omics provides the consensus-scored SEPHS1P4 profile across patient tissues and cancer cell-line models. SEPHS1P4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SEPHS1P4 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, SEPHS1P4 RNA expression shows 12,641 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where SEPHS1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPHS1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPHS1P4 survival associations across molecular data types. SEPHS1P4 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPHS1P4 RNA expression–survival associations across cancer types. High SEPHS1P4 expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in LUSC, UCS and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SEPHS1P4 RNA expression.
This table summarizes SEPHS1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SEPHS1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPHS1P4 shows higher tumor expression in COAD, UCEC, BRCA, STAD, LUSC and HNSC. The COAD box plot shows higher SEPHS1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.581, t-test p < 0.001).
This table shows molecular features associated with SEPHS1P4 in patient tissues and cancer cell lines. In patient samples, SEPHS1P4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
